Royal Manchester Children’s Hospital (RMCH) has introduced a UVC system in an effort to combat healthcare-acquired infections.
There is a large variation in hospital infection rates across the UK, with the worst performers having more than five times the number of cases than the best performing hospitals.
As part of their ongoing effort to combat HCAIs, RMCH has added the Surfacide Helios Ultraviolet C (UV-C) disinfection system to its cleaning protocol. Helios is a triple-emitter UV-C hard surface disinfection system that eradicates multi-drug resistant organisms in the patient environment
RMCH is the first hospital within the NHS and indeed the UK to join other leading healthcare systems worldwide that are turning to UV-C technology as a complement to traditional cleaning methods. The hospital will be deploying four UV-C Disinfection Systems (12 emitters) throughout the hospital to protect patients and staff.
“Our number one goal is to keep our patients safe, not only through the advanced care we provide, but also through the environment in which we provide that care,” said Julie Jolly, matron – service improvement, enhanced recovery and care co-crdination,and V2A programme lead (children’s) , for Royal Manchester Children’s Hospital. “We are extremely pleased with the efficacy and impact of Surfacide’s Helios system in protecting our patients from the bacteria and viruses that can cause HAIs.”
RMCH conducted an independent pilot study using the UV-C Disinfection System in the hospital’s Oncology/Haematology Unit. The eight month independent study compared standard cleaning protocols alone to those including Surfacide Helios UV-C Disinfection. The result was an 83.7% decrease in contaminated sites and a 43% decrease in HAIs when the Helios system was introduced into the patient environment along with standard cleaning procedures.
“HAIs create significant health risks and cost the healthcare industry billions of dollars each year. That toll has placed a high priority on innovative technologies such as UV-C disinfection,” said Gunner Lyslo, founder and CEO of Surfacide, LLC. “We are proud to work with the team at the Royal Manchester Hospital and help them lead the way when it comes to patient safety and we look forward to our continued partnership.”
